KR20240082356A - 조작된 tgf-베타 단량체 및 사용 방법 - Google Patents

조작된 tgf-베타 단량체 및 사용 방법 Download PDF

Info

Publication number
KR20240082356A
KR20240082356A KR1020247012779A KR20247012779A KR20240082356A KR 20240082356 A KR20240082356 A KR 20240082356A KR 1020247012779 A KR1020247012779 A KR 1020247012779A KR 20247012779 A KR20247012779 A KR 20247012779A KR 20240082356 A KR20240082356 A KR 20240082356A
Authority
KR
South Korea
Prior art keywords
tgf
seq
amino acid
substitution
monomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247012779A
Other languages
English (en)
Korean (ko)
Inventor
앤드류 피. 힌크
크리스틴 드포
그렉 엠. 델고페
Original Assignee
유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 filed Critical 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션
Publication of KR20240082356A publication Critical patent/KR20240082356A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020247012779A 2021-10-11 2022-10-11 조작된 tgf-베타 단량체 및 사용 방법 Pending KR20240082356A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163254249P 2021-10-11 2021-10-11
US63/254,249 2021-10-11
PCT/US2022/077879 WO2023064747A1 (en) 2021-10-11 2022-10-11 Engineered tgf-beta monomers and methods of use

Publications (1)

Publication Number Publication Date
KR20240082356A true KR20240082356A (ko) 2024-06-10

Family

ID=85988028

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247012779A Pending KR20240082356A (ko) 2021-10-11 2022-10-11 조작된 tgf-베타 단량체 및 사용 방법

Country Status (9)

Country Link
US (1) US20240425559A1 (https=)
EP (1) EP4416172A4 (https=)
JP (1) JP2024537234A (https=)
KR (1) KR20240082356A (https=)
CN (1) CN118103390A (https=)
AU (1) AU2022367394B2 (https=)
CA (1) CA3232809A1 (https=)
TW (1) TW202330579A (https=)
WO (1) WO2023064747A1 (https=)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW517059B (en) * 1994-07-25 2003-01-11 Ciba Geigy Ag New process for the production of biologically active protein
US11091523B2 (en) * 2016-11-18 2021-08-17 University of Pittsburgh—of the Commonwealth System of Higher Education Engineered TGF-β monomers and their use for inhibiting TGF-β signaling
JP2023539195A (ja) * 2020-08-27 2023-09-13 ユニバーシティ オブ ピッツバーグ － オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 組換えトランスフォーミング増殖因子（ｔｇｆ）－ベータ単量体をコードする腫瘍溶解性ウイルスおよびその使用

Also Published As

Publication number Publication date
AU2022367394B2 (en) 2026-03-19
TW202330579A (zh) 2023-08-01
CN118103390A (zh) 2024-05-28
AU2022367394A1 (en) 2024-04-11
CA3232809A1 (en) 2023-04-20
JP2024537234A (ja) 2024-10-10
WO2023064747A1 (en) 2023-04-20
EP4416172A4 (en) 2025-12-17
US20240425559A1 (en) 2024-12-26
EP4416172A1 (en) 2024-08-21

Similar Documents

Publication Publication Date Title
AU2019218786B2 (en) Cell-permeable stapled peptide modules for cellular delivery
US20100081611A1 (en) Stabilized maml peptides and uses thereof
AU2014293386B2 (en) Cyclic polypeptides for the treatment of heart failure
EP2917244B1 (en) Aprotinin-derived polypeptide-antibody conjugates
BR122020010972B1 (pt) polipeptídeo isolado e de fusão, sua composição farmacêutica e multímero
CA2950718A1 (en) Composition for treating diabetes mellitus comprising insulin and a glp-1/glucagon dual agonist
AU2013305885A1 (en) Molecules with antigen binding and polyvalent Fc gamma receptor binding activity
JP6279788B2 (ja) 抗癌剤に起因する末梢性神経障害性疼痛の予防及び／又は治療剤
CA3161364A1 (en) Combination therapy using an il-2 receptor agonist and an immune checkpoint inhibitor
CN109134664B (zh) 一种经修饰的生长分化因子及其制备方法和应用
AU2018383633B2 (en) Selective targeting of apoptosis proteins by structurally-stabilized and/or cysteine-reactive NOXA peptides
US11033609B2 (en) Cyclic acetylcholinesterase C-terminal peptide in the treatment or prevention of cancer or metastasis
CN115768458A (zh) CEBP-β拮抗剂的施用和使用方法
US20150297680A1 (en) Compositions and methods for increasing protein half-life
KR20240082356A (ko) 조작된 tgf-베타 단량체 및 사용 방법
JP2021506772A (ja) 視神経脊髄炎の処置のための組換えＩｇＧ Ｆｃ多量体
CN102993314A (zh) 一种抗肿瘤融合蛋白及其制备方法和用途
HK40109585A (zh) 工程化TGF- β单体及其使用方法
JP7375163B2 (ja) Ｔｇｆ－ベータトラップ
CA3219685A1 (en) Composition for preventing or treating non-alcoholic fatty liver disease or non-alcoholic steatohepatitis comprising growth differentiation factor-15 variant
JP2023524558A (ja) Ｐｃｎａ相互作用モチーフを含むペプチドの固形癌の治療における使用
JP2025509985A (ja) 免疫原性細胞死適用のためのシステムおよび方法
HK40044828A (en) Medication for alleviating symptoms of peripheral neuropathy caused by anticancer drug and/or suppressing onset of peripheral neuropathy
WO2018130659A1 (en) Therapeutic peptides that target tgf-beta interaction
HK1203846B (en) Agent for preventing and/or treating peripheral neuropathic pain caused by anti-cancer drug

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000